CHMP says yes to Novartis eye drug but no to its heart treatment, yes to Biogen Idec MS treatment;

@FiercePharma: Takeda now 5 for 6 in winning Actos cases, but that loss was a stunner. Article | Follow @FiercePharma

@TracyStaton: Some AstraZeneca investors are balking at the board's Pfizer snub. Others are practically high-fiving Chairman Johannson. Story | Follow @TracyStaton

@EricPFierce: So you thought you would get through the holidays without more Pfizer/AstraZeneca news? Not a chance. More | Follow @EricPFierce

@CarlyHFierce: Ok, this Rolaids-sponsored spelling bee just passed vaccine car seats for my favorite thing today. Article | Follow @CarlyHFierce

> Europe's Committee for Medicinal Products for Human Use (CHMP) has recommended approval of a drug for treating glaucoma from Novartis' ($NVS) Alcon unit. Release

> CHMP recommended against approval of Novartis' heart failure drug serelaxin, a product it hopes could make up for lost sales when generics of blockbuster heart drug Diovan finally hit. Story

> CHMP recommended in favor of approval Biogen Idec's ($BIIB) Plegridy for treating multiple sclerosis. Story

> Janssen Biologics has withdrawn its application in Europe to add an intravenous form of its rheumatoid arthritis drug Simponi after regulators there asked for more data. Report

> Local government officials in Hangzhou, China on Friday said their visit to local offices of Roche ($RHHBY) was routine and unrelated to the anti-bribery investigation that has embroiled GlaxoSmithKline ($GSK) in China. Report

> The FDA asked Internet service providers to close 1,975 websites for selling drugs illegally as part the recent 10-day, international sweep against counterfeit drugs. Release

Medical Device News

@FierceMedDev: Atossa board adopts 'poison pill' remedy in wake of FDA crackdown. More | Follow @FierceMedDev

@VarunSaxena2: After months of silence, FDA returns to name and shame strategy on pediatric trial compliance. Story | Follow @VarunSaxena2

@MichaelGFierce: Smallest, fastest nanomotor moves drugs and releases them on demand. Article | Follow @MichaelGFierce

@EmilyWFierce: Doctors in Italy designed a mini dialysis machine that could save the lives of infants. More | Follow @EmilyWFierce

> iRhythm secures $17 million from VCs for its arrhythmia monitor. News

> Power morcellator fallout continues after FDA advisory warning. More

> J&J: Expect more consolidation in orthopedics industry. Story

Biotech News

@FierceBiotech: This week's EuroBiotech Report: AZ and Europe's 'innovation malaise,' €30M Irish life sci fund, and more. Report | Follow @FierceBiotech

@JohnCFierce: So, something has changed at the CHMP on conditional approvals, and I don't know what it is. Can anyone fill in the blanks here? | Follow @JohnCFierce

@DamianFierce: PTC convinces CHMP to change its mind on conditional approval of the DMD drug ataluren. Story | Follow @DamianFierce

@EmilyMFierce: Beware! Crackpot science: Article. File under: Why I don't watch TV news. | Follow @EmilyMFierce

> Lilly, Boehringer pick up EU nod for FDA-spurned diabetes treatment. More

> The EU's not impressed with Novartis' 'breakthrough' cardio drug, either. Story

> Former CDER official joins Greenleaf Health, biosimilars experience in tow. Chutes & Ladders

And Finally... The wide variety of Type 2 diabetes drugs on the market may be confusing patients and needlessly raising the cost of treatment. Story

Suggested Articles

In previously untreated nonsquamous NSCLC, a Tyvyt-chemo combo beat chemo alone at stalling the time to tumor progression or death.

It’s been a big year for Bristol's Opdivo-Yervoy combo in lung cancer, but with new mesothelioma data in hand, the duo isn’t done making headlines.

A third spinal muscular atrophy treatment option is set to debut with the FDA’s approval for Roche’s Evrysdi, formerly known as risdiplam.